Tuesday, July 28, 2015 10:10:21 AM
Progress happened 'Dude'.
Fact is,.... scale-up to 200 g of 'Cides has been done.
The work done in the old facility and used to generate the much smaller quantities that were sufficient for the small animal testing was not sufficient to get TOX testing started.
However, TOX testing was started and completed using 'Cides generated using at least 200 g scale syntheses.
That segment of scale-up was done in the old facility and that particular batch of scaled-up material was used to do the first TOX testing.
None of what is in the statement from last year that is being listed as a negative or a 'lie' is - in fact - inaccurate.
Production-level scale-up isn't complete in that currently (as far as we know here on the outside) the company cannot produce Kg-level quantities of 'Cides of sufficient quality to use to complete TOX testing or move into early-stage clinical testing.
However - the neither the company, nor I, have claimed that Kg-level synthesis scale-up is completed.
To make statements otherwise is intentionally ignore that scale-up is incremental.
200 g can be done - previously those quantities could not be made.
500 g reportedly can be done (although we are waiting to hear that the quality is sufficient and the process acceptably repeatable) - previously they were limited to 200 g max. Next stop - Kg quantities.
The argument on this front is moot. The statement that is being touted as a negative is actually accurate.
This "conversation" is done.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM